title: Molecular Updates in Prostate Cancer.
abstract: A wide array of molecular markers and genomic signatures, reviewed in this article, may soon be used as adjuncts to currently established screening strategies, prognostic parameters, and early detection markers. Markers of genetic susceptibility to PCA, recurrent epigenetic and genetic alterations, including ETS gene fusions, PTEN alterations, and urine-based early detection marker PCA3, are discussed. Impact of recent genome-wide assessment on our understanding of key pathways of PCA development and progression and their potential clinical implications are highlighted.
authors.affiliation: Johns Hopkins University, Baltimore, Maryland, USA. Electronic address: gnetto1@jhmi.edu.
authors.forename: George J
authors.initials: GJ
authors.lastname: Netto
mesh_terms: D000951:Antigens, Neoplasm / Q000652:urine; D014408:Biomarkers, Tumor / Q000652:urine; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D004781:Environmental Exposure / Q000009:adverse effects; D044127:Epigenesis, Genetic; D016147:Genes, Tumor Suppressor; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D010375:Pedigree; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000235:genetics*; D059467:Transcriptome
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C479341:prostate cancer antigen 3, human
keywords: Carcinogenesis; Genomic classification; PCA3; Prostate cancer